The Role of T/NK Cells in Anti-tumor Immunity

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (25 November 2023) | Viewed by 2968

Special Issue Editors


E-Mail Website
Guest Editor
Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Interests: innate immunity; tumor immunology; natural killer cells; innate lymphoid cells; tumor microenvironment; cancer immunotherapy; immunocheckpoints
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Interests: NK cells; αβ T cells; γδ T cells; myeloid-derived suppressor cells; immunotherapy; tumor microenvironment

Special Issue Information

Dear Colleagues, 

We are pleased to invite you to participate in this Special Issue focalized in tumor-infiltrating lymphocytes (TILs). TILs consist of all lymphocytic cell populations that have invaded the tumor tissue. TILs have been described in a number of solid tumors, but also play an important role in hematological malignancies. TILs are comprised primarily of cytotoxic (CD8+) and helper (CD4+) T-cells, and a smaller proportion of gamma/delta T and NK cells. Tumor-associated soluble factors and cells interacting with TILs could mediate immune evasion and tumor growth.

This Special Issue aims to dissect the cross-talk occurring in TME, helping to identify new potential biomarkers, therapeutic targets and possibly to develop novel protocols of anti-tumor immunotherapy.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: NK cells, alfa/beta T cells, gamma/delta T cells, CAR cells, monoclonal antibodies, inhibitory checkpoints, solid and hematological tumors, anti-tumor activity, tumor therapy, immunotherapy, immune-based therapy, and immune evasion.

We look forward to receiving your contributions.

Dr. Paola Vacca
Dr. Nicola Tumino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • innate immunity
  • NK cells
  • α/β T cells
  • γ/δ T cells
  • anti-tumor activity
  • tumor therapy
  • immunotherapy
  • immune-based therapy
  • TME
  • immunoscore

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 807 KiB  
Review
The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies
by Maria G. Desimio, Daniela A. Covino, Beatrice Rivalta, Caterina Cancrini and Margherita Doria
Cancers 2023, 15(6), 1914; https://doi.org/10.3390/cancers15061914 - 22 Mar 2023
Cited by 5 | Viewed by 2465
Abstract
The Epstein–Barr virus (EBV) is a ubiquitous herpesvirus most often transmitted during infancy and infecting the vast majority of human beings. Usually, EBV infection is nearly asymptomatic and results in life-long persistency of the virus in a latent state under the control of [...] Read more.
The Epstein–Barr virus (EBV) is a ubiquitous herpesvirus most often transmitted during infancy and infecting the vast majority of human beings. Usually, EBV infection is nearly asymptomatic and results in life-long persistency of the virus in a latent state under the control of the host immune system. Yet EBV can cause an acute infectious mononucleosis (IM), particularly in adolescents, and is associated with several malignancies and severe diseases that pose a serious threat to individuals with specific inborn error of immunity (IEI). While there is a general consensus on the requirement for functional CD8 T cells to control EBV infection, the role of the natural killer (NK) cells of the innate arm of immunity is more enigmatic. Here we provide an overview of the interaction between EBV and NK cells in the immunocompetent host as well as in the context of primary and secondary immunodeficiencies. Moreover, we report in vitro data on the mechanisms that regulate the capacity of NK cells to recognize and kill EBV-infected cell targets and discuss the potential of recently optimized NK cell-based immunotherapies for the treatment of EBV-associated diseases. Full article
(This article belongs to the Special Issue The Role of T/NK Cells in Anti-tumor Immunity)
Show Figures

Figure 1

Back to TopTop